About me
Dr Dunhui Li (Oliver) joined the Personalised Medicine Centre (formerly Centre for Molecular Medicine and Innovative Therapeutics) as a PhD student in Professor Steve Wilton’s laboratory and on completing his PhD in 2020, remained at the Centre as a postdoctoral scientist in the MND group led by Professor Anthony Akkari. His research funding track record is outstanding for an early career researcher with involvement in grants worth $1.4 million. Oliver’s PhD included a study on the PARK2 gene – whose product, the protein, parkin, plays a crucial role in programmed cell death – for which he developed an antisense therapeutic capable of restoring parkin expression as a potential treatment for a rare form of Parkinson’s disease. Building on the expertise he gained at our Centre, Oliver has moved to Yale University – one of the world’s top 10 universities – to work as a postdoctoral fellow in the Adams Center for Parkinson’s Disease Research led by Professor Clemens Scherzer, where he will focus on developing novel RNA therapies for patients with Parkinson’s disease. Oliver is an Honorary Research Fellow with the Personalised Medicine Centre.